FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3093622243> ?p ?o ?g. }

• W3093622243 endingPage "e883" @default.
• W3093622243 startingPage "e882" @default.
• W3093622243 abstract "To assess efficacy and toxicity of salvage stereotactic body radiation therapy (S-SBRT) for recurrent local and locoregional prostate cancer. A prospective IRB approved clinical database was reviewed to extract a cohort of 30 consecutive patients who received re-irradiation between 2015-2018 following failure of external beam radiotherapy (n = 25) or brachytherapy (n = 5) detected by rising PSA and positive PSMA PET-CT findings. One third of these patients (n = 10) had received Androgen Deprivation Therapy (ADT) only for biochemical failure and were referred for a local salvage treatment following emergence of castrate-resistant prostate cancer (CRPC). Histologic confirmation of recurrence was obtained in 17 patients. Hydrogel spacers or endo-rectal balloons were used in 6 and 18 patients to protect the rectum. Patients were treated with full bladder. PSA failure was according to the Phoenix definition. Toxicity was reported using CTCAE v5.0, acute <3 months, late >3 months. Seventeen patients received whole-gland radiation and 13 patients focal prostate treatment to the PSMA-avid lesion. In addition, eight patients also received 25Gy in 5 fractions to PSMA-avid pelvic nodes. Median dose of S-SBRT was 5 fractions of 6.5Gy (range: 6-8Gy). Short term ADT was initiated with S-SBRT in fifteen patients. Median time from primary radiation to S-SBRT was 9 years (range: 2-20 years). Median follow-up following S-SBRT was 23 months (range: 7-71 months). Biochemical and clinical failures developed in 14 out of 30 patients (47%), of which 3 were in-field, 2 were regional and 9 developed bone metastasis, thus local control of S-SBRT to the prostate was 90%. Median time to failure was 16 months (range: 3-36 months). Failure occurred in 8 out of 10 CRPC patients versus 6 out of 20 castrate-naïve patients (80% vs 30%, p = 0.009). One patient was lost to follow-up after 12 months, thus 15 patients (50%) had no evidence of disease at a median follow-up of 19 months. Acute grade 2 GU toxicity, primarily cystitis, occurred in 8 patients (27%) and 1 patient (3%) had grade 3 hematuria. Late grade 2 GU toxicity was 27% (n = 8) and 1 patient (3%) had a grade 3 urethral stricture. There was no ≥ grade 2 acute GI toxicity. Late grade 2 GI incontinence occurred in 1 patient (3%) with no grade 3 events. One patient developed late grade 3 osteomyelitis pubis following treatment. S-SBRT is associated with favorable local control and acceptable toxicity and thus should be further studied as an early salvage option which could potentially spare toxicity of lifelong hormonal therapy. Patients with non-metastatic castrate resistant disease were more prone to rapidly develop distant metastasis following S-SBRT." @default.
• W3093622243 created "2020-10-29" @default.
• W3093622243 creator A5013382474 @default.
• W3093622243 creator A5028313700 @default.
• W3093622243 creator A5034776385 @default.
• W3093622243 creator A5040293489 @default.
• W3093622243 creator A5062199973 @default.
• W3093622243 creator A5074978564 @default.
• W3093622243 creator A5078948310 @default.
• W3093622243 date "2020-11-01" @default.
• W3093622243 modified "2023-09-25" @default.
• W3093622243 title "Re-Irradiation with Extreme Hypo-Fractionation to the Prostate for Local Recurrence after Primary Radiotherapy" @default.
• W3093622243 doi "https://doi.org/10.1016/j.ijrobp.2020.07.477" @default.
• W3093622243 hasPublicationYear "2020" @default.
• W3093622243 type Work @default.
• W3093622243 sameAs 3093622243 @default.
• W3093622243 citedByCount "0" @default.
• W3093622243 crossrefType "journal-article" @default.
• W3093622243 hasAuthorship W3093622243A5013382474 @default.
• W3093622243 hasAuthorship W3093622243A5028313700 @default.
• W3093622243 hasAuthorship W3093622243A5034776385 @default.
• W3093622243 hasAuthorship W3093622243A5040293489 @default.
• W3093622243 hasAuthorship W3093622243A5062199973 @default.
• W3093622243 hasAuthorship W3093622243A5074978564 @default.
• W3093622243 hasAuthorship W3093622243A5078948310 @default.
• W3093622243 hasBestOaLocation W30936222431 @default.
• W3093622243 hasConcept C121608353 @default.
• W3093622243 hasConcept C126322002 @default.
• W3093622243 hasConcept C126838900 @default.
• W3093622243 hasConcept C126894567 @default.
• W3093622243 hasConcept C141071460 @default.
• W3093622243 hasConcept C155806632 @default.
• W3093622243 hasConcept C188816634 @default.
• W3093622243 hasConcept C2775908122 @default.
• W3093622243 hasConcept C2776235491 @default.
• W3093622243 hasConcept C2776694085 @default.
• W3093622243 hasConcept C2777008409 @default.
• W3093622243 hasConcept C2777416452 @default.
• W3093622243 hasConcept C2777899217 @default.
• W3093622243 hasConcept C2779466945 @default.
• W3093622243 hasConcept C2780192828 @default.
• W3093622243 hasConcept C2780775027 @default.
• W3093622243 hasConcept C2781074409 @default.
• W3093622243 hasConcept C509974204 @default.
• W3093622243 hasConcept C71924100 @default.
• W3093622243 hasConceptScore W3093622243C121608353 @default.
• W3093622243 hasConceptScore W3093622243C126322002 @default.
• W3093622243 hasConceptScore W3093622243C126838900 @default.
• W3093622243 hasConceptScore W3093622243C126894567 @default.
• W3093622243 hasConceptScore W3093622243C141071460 @default.
• W3093622243 hasConceptScore W3093622243C155806632 @default.
• W3093622243 hasConceptScore W3093622243C188816634 @default.
• W3093622243 hasConceptScore W3093622243C2775908122 @default.
• W3093622243 hasConceptScore W3093622243C2776235491 @default.
• W3093622243 hasConceptScore W3093622243C2776694085 @default.
• W3093622243 hasConceptScore W3093622243C2777008409 @default.
• W3093622243 hasConceptScore W3093622243C2777416452 @default.
• W3093622243 hasConceptScore W3093622243C2777899217 @default.
• W3093622243 hasConceptScore W3093622243C2779466945 @default.
• W3093622243 hasConceptScore W3093622243C2780192828 @default.
• W3093622243 hasConceptScore W3093622243C2780775027 @default.
• W3093622243 hasConceptScore W3093622243C2781074409 @default.
• W3093622243 hasConceptScore W3093622243C509974204 @default.
• W3093622243 hasConceptScore W3093622243C71924100 @default.
• W3093622243 hasIssue "3" @default.
• W3093622243 hasLocation W30936222431 @default.
• W3093622243 hasOpenAccess W3093622243 @default.
• W3093622243 hasPrimaryLocation W30936222431 @default.
• W3093622243 hasRelatedWork W2042143271 @default.
• W3093622243 hasRelatedWork W2085529113 @default.
• W3093622243 hasRelatedWork W2138863125 @default.
• W3093622243 hasRelatedWork W2529939135 @default.
• W3093622243 hasRelatedWork W2597301728 @default.
• W3093622243 hasRelatedWork W2946095553 @default.
• W3093622243 hasRelatedWork W2972392603 @default.
• W3093622243 hasRelatedWork W3217230954 @default.
• W3093622243 hasRelatedWork W4310112889 @default.
• W3093622243 hasRelatedWork W71823916 @default.
• W3093622243 hasVolume "108" @default.
• W3093622243 isParatext "false" @default.
• W3093622243 isRetracted "false" @default.
• W3093622243 magId "3093622243" @default.
• W3093622243 workType "article" @default.